The number of patients with end-stage heart failure (HF) continues to increase over time, but there has been little change in the availability of organs for cardiac transplantation, intensifying the demand for left ventricular assist devices (LVADs) as a bridge to transplantation. There is also a growing number of patients with end-stage HF who are not transplant candidates but may be eligible for long-term support with an LVAD, known as destination therapy. Due to this increasing demand, LVAD technology has evolved, resulting in transformative improvements in outcomes. Additionally, with growing clinical experience patient management continues to be refined, leading to iterative improvements in outcomes. With outcomes continuing to improve, the potential benefit from LVAD therapy is being considered for patients earlier in their course of advanced HF. We review recent changes in technology, patient management, and implant decision making in LVAD therapy.

中文翻译：

---

用于末期心力衰竭的心室辅助设备的创新。

终末期心力衰竭（HF）的患者人数随着时间的推移而继续增加，但是用于心脏移植的器官的可用性几乎没有变化，这增加了对左心室辅助装置（LVAD）作为移植桥梁的需求。越来越多的晚期HF患者不是移植候选者，但可能有资格接受LVAD的长期支持，这被称为目的地疗法。由于需求的增长，LVAD技术得到了发展，从而带来了成果的革命性改进。此外，随着临床经验的增长，患者管理将不断完善，从而导致结果的迭代改善。随着成果的不断改善，对于晚期HF患者，正在考虑LVAD治疗的潜在益处。我们回顾了LVAD治疗技术，患者管理和植入决策方面的最新变化。